Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inebilizumab vs Rituximab in Relapsed/Refractory DLBCL
NCT01453205Phase 2Completed
- Sponsor
- MedImmune
- Start
- Feb 2012
- Primary completion
- Jul 2016
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of inebilizumab in diffuse large B-cell lymphoma (DLBCL), sponsored by MedImmune. Started Feb 2012; status: completed.
02
Drugs
inebilizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01453205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01453205.